Concord Biotech said that the U.S. Food and Drug Administration (US FDA) had successfully concluded the inspection of the company’s Valthera Formulation Facility, with one minor procedural observation.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.